Analysis: No Risk Differences in MACE and VTE Among Biologics for Psoriatic Disease

A recent cohort analysis revealed no significant differences in the risks of major adverse cardiovascular events (MACE) and venous thromboembolic events (VTE) among biologic-naïve patients with psoriasis or psoriatic arthritis (PsA) treated with different classes of biologics.

Researchers used data from the TriNetX Research Network and assessed 32,098 patients who initiated biologic therapy between 2014 and 2022. Patients were divided into treatment groups based on their first biologic prescription: TNF inhibitors (TNFi, 20,314 patients), IL-17 inhibitors (IL-17i, 5,073 patients), IL-12/23 inhibitors (IL-12/23i, 3,573 patients), and IL-23 inhibitors (IL-23i, 3,138 patients). Using propensity-matched cohorts, the researchers compared MACE and VTE risks across the groups.

The data revealed no significant differences were found in MACE or VTE risk between any of the biologic classes in the overall population, a finding supported by subgroup analyses (including those stratified by psoriasis or PsA). In patients with pre-existing hyperlipidemia and diabetes mellitus, the risks of MACE and VTE were lower with novel biologics (IL-17i, IL-12/23i, or IL-23i) vs. TNFi.

The lack of data on psoriasis severity in the dataset was cited as a study limitation.

"Among patients with psoriasis or PsA, no significant risk differences of MACE and VTE were detected between those with IL-17i, IL-12/23i, IL-23i and those with TNFi," the authors concluded. "These findings can serve as a reference to healthcare providers and patients when making clinical decisions, thereby also providing evidence for future pharmacovigilance research."

Source: